Acasti Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 12, 2024
GRCE$1.87+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Shareholders’ Equity
ACASTI PARMA INC.
Condensed Consolidated Interim Statements of Shareholders' Equity
| Common Shares | ||||||
|---|---|---|---|---|---|---|
| (Expressed in thousands except share data) | Number | Dollar | Additionalpaid-incapital | Accumulatedothercomprehensiveloss | Accumulated deficit | Total stockholders' equity |
| $ · $ · $ · $ · $ | ||||||
| Balance, March 31, 2023 | 7,435,533 | 258,294 | 13,965 | (6,038) | (198,266) | 67,955 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (4,023) | (4,023) |
| Stock-based compensation | — | — | 78 | — | — | 78 |
| Balance at June 30, 2023 | 7,435,533 | 258,294 | 14,043 | (6,038) | (202,289) | 64,010 |
| Issuance of common shares and pre-funded warrants through private placement, net of offering costs | 1,951,371 | 2,744 | 2,963 | — | — | 5,707 |
| Issuance of common shares upon the exercise of stock options | 12,500 | — | 21 | — | — | 21 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (3,273) | (3,273) |
| Stock-based compensation | — | — | 280 | — | — | 280 |
| Balance at September 30, 2023 | 9,399,404 | 261,038 | 17,307 | (6,038) | (205,562) | 66,745 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (2,391) | (2,391) |
| Stock-based compensation | — | — | 326 | — | — | 326 |
| Balance at December 31, 2023 | 9,399,404 | 261,038 | 17,633 | (6,038) | (207,953) | 64,680 |
| Common Shares | ||||||
|---|---|---|---|---|---|---|
| (Expressed in thousands except for share data) | Number | Dollar | Additionalpaid-incapital | Accumulatedothercomprehensiveloss | Accumulated deficit | Total stockholders' equity |
| $ · $ · $ · $ · $ | ||||||
| Balance, March 31, 2022 | 7,381,425 | 257,990 | 12,154 | (6,037) | (155,837) | 108,270 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (4,524) | (4,524) |
| Cumulative translation adjustment | — | — | — | (2) | — | (2) |
| Stock-based compensation | — | — | 464 | — | — | 464 |
| Net proceeds from shares issued under the at-the-market (ATM) program | 34,335 | 195 | — | — | — | 195 |
| Balance at June 30, 2022 | 7,415,760 | 258,185 | 12,618 | (6,039) | (160,361) | 104,403 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (4,929) | (4,929) |
| Cumulative translation adjustment | — | — | — | (1) | — | (1) |
| Net proceeds from shares issued under the at-the-market (ATM) program | 19,773 | 109 | — | — | — | 109 |
| Stock-based compensation | — | — | 582 | — | — | 582 |
| Balance at September 30, 2022 | 7,435,533 | 258,294 | 13,200 | (6,040) | (165,290) | 100,164 |
| Net loss and total comprehensive loss for the period | — | — | — | — | (3,889) | (3,889) |
| Cumulative translation adjustment | — | — | — | 2 | — | 2 |
| Stock-based compensation | — | — | 443 | — | 443 | |
| Balance at December 31, 2022 | 7,435,533 | 258,294 | 13,643 | (6,038) | (169,179) | 96,720 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.